Mesenchymal stem cells treatment in COVID-19 patient with multi-organ involvement

Abstract

The aim of this study is to evaluate the therapeutic effect of mesenchymal stem cells (MSCs) in a severe case of brain and multiple organ involvement in a patient with COVID-19. Here, a 51-year-old male patient with multi-organ involvement due to COVID-19 infection and developing cardiac arrest is presented. MSCs were transplanted to the patient four times systematically and once intrathecally. As a result, the application of MSCs has been found to have a healing effect on organs in this patient with severe COVID-19 infection. In addition, transplantation of MSCs both systematically and intrathecally is considered to be effective in the treatment of the central nervous system (Tab. 2, Fig. 2, Ref. 24).

The safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-associated pneumonia: a systematic review and meta-analysis

“…Abstract and full-text screening identified 22 studies with 371 patients to be included for the data extraction. All included studies were assessed as good [10,12,[22][23][24][25][26]32,35,36,38,39] or fair [13,[27][28][29][30][31]33,34,37,40] according to the NHLBI quality assessment tool (Table S2).…”

“…Culture-expanded allogeneic MSCs were used in all 22 included studies. Allogeneic umbilical cordderived MSCs were used in studies [22][23][24][25][26]29,30,32,34,[36][37][38][39], Wharton's jelly-derived MSCs in three studies [12,33,40], menstrual blood-or adipose tissue-or placenta-derived MSCs were separately used in one study [10,28,35]. Four studies did not report the tissue origin of the MSCs [13,27,31,37](Table 3).…”

“…Eleven studies reported on baseline oxygenation indicators of patients [10,13,26,27,29,30,32,35,37,38,40]. General symptoms such as fever, cough, and dyspnea were reported in 16 studies [10,12,13,23,24,27,29,[32][33][34][35][36][37][38][39][40], and lung imaging evaluation showed COVID-19 related pneumonia in 15 studies [10,12,23,25,27,29,[32][33][34][35][36][37][38][39][40].…”

“…The disease severity of the patient's condition was Critical (n = 63), Severe (n = 260), and Moderate (n = 10) in 19 studies [10,12,13,[22][23][24][25][27][28][29][30][31][32][33][34]36,[38][39][40]; and the patients in one study were divided into "Mild-to-moderate" (n = 6) and "Moderate-to-severe" (n = 18) according to the severity of ARDS [26]. The average age of study participants was 45.1 to 61.0 years for MSCs group and 39.0 to 65.0 years for control group in the comparative studies [13,[22][23][24][25][26][27].…”

“…The most common comorbidities including hypertension (HT, n = 105), diabetes mellitus (DM, n = 61), obesity(n = 19), chronic obstructive pulmonary disease (COPD, n = 11), and heart disease (HD, n = 9) had been reported in 18 studies [10,12,13,22,23,[25][26][27][28][29][30][32][33][34][35][38][39][40]. There were also differences in the follow-up time after MSCs treatment in these studies, ranging from a week to two months, which mainly due to the point when patients were recovery or died and discharge from the hospital (Table 1-2).…”